Evidence item

The passage directly reports the study population, comparator, adjusted odds ratios, and confidence intervals for hospitalization and disease progression. DATASET_RESULT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 15968

Source: Metformin use and decreased risk of severe COVID-19 outcomes in a real-world case-control study · locator {} · excerpt hash sha256:1c681bcd51cd5a37d46cc4e93486257009a1b1eaa383229f2fa19ab306d25561

Our study covered 81,348 subjects. Of these, 29,568 had a PCR+ test, 2753 of whom were admitted to hospital. According to our results, prior metformin use reduces the risk of hospitalisation (aOR 0.70; 95%CI 0.51–0.97) and progression of COVID-19 (aOR 0.66; 95%CI 0.45–0.98) among metformin users when compared with those not taking antidiabetic medication.